GlomCon's Clinical Trial Portal

A platform to help HOPE
find OPPORTUNITY

Study Sponsor: Novartis Pharmaceuticals

Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy (APPELHUS).

Study Sponsor: Novartis Pharmaceuticals

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN (APPARENT).

Study Sponsor: Novartis Pharmaceuticals

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. (APPEAR-C3G).

Study Sponsor: Novartis Pharmaceuticals

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN).

We gratefully acknowledge the support and partnership of corporations dedicated to improving the lives of patients with glomerular diseases.

The support from our corporate members and our strategic partners allows us to come up with bold ideas and helps us pursue our mission.

Questions? Concerns? Reach out to GlomCon's Clinical Trials team at support@glomcon.org